Advertisement

Studies on the in Vivo Synthesis of Methotrexate Polyglutamates and their Efflux Properties in Normal, Proliferative, and Neoplastic Mouse Tissues

  • Richard G. Poser
  • Francis M. Sirotnak
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 163)

Summary

Synthesis of poly-γ-glutamyl metabolites of methotrexate was demonstrated in mouse small intestine, liver and bone marrow, and in L1210 leukemia, Sarcoma 180 and Ehrlich tumor cells after sc injections of [3H]methotrexate to tumor bearing mice. Ion exchange chromatography of tissue extracts resolved six peaks of radioactivity believed to represent methotrexate and metabolites with up to 4 additional glutamyl residues. Polyglutamate formation in L1210 cells and small intestine was shown to be independent of dose at least to 400 mg/kg as long as intracellular levels of drug in excess of the di-hydrofolate reductase binding capacity (exchangeable) were maintained. Both the total amount of polyglutamates and the average length of the polyglutamyl chain increased with time as long as exchangeable level of drug were present intracellularily. The results also showed differences in the extent of metabolism of methotrexate polyglutamates among the tissues examined. Although, these differences were at times very large, there was no consistent correlation between these differences and other pharmacologic parameters or cytoxicity. Tumor cells appeared to synthesize more polyglutamates than the normal tissues examined. However, differences in total drug persistence and sensitivity to drug among tumor cells and among normal tissues did not reflect the relative extent of poly-glutamate synthesis in each group. We observed no selective retention of polyglutamates as compared to methotrexate by L1210 cells in vitro as indicated by the extracellular accumulation during efflux of methotrexate and the polyglutamates. This could only be demonstrated by allowing efflux of intracellular drug in the presence of extracellular dihydrofolate reductase, which averted hydrolysis of the polyglutamates. It is concluded that the extent of polyglutamate synthesis per se may not be a determinant of drug sensitivity in murine tissues. However, the accumulation of these metabolites may contribute in some way to overall therapeutic response or relative cytotoxicity.

Keywords

Hydrolysis Leukemia Titration Carboxyl Syringe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baugh, C. M., Krumdiek, C. L., and Nair, M. G., Biochem. Bio-phys. Res. Commun., 52, 27–34 (1973).CrossRefGoogle Scholar
  2. 2.
    Gerwitz, D. A., White, J. C, Randolph, J. K., and Goldman, I. D., Cancer Res., 39, 2914–2918 (1979).Google Scholar
  3. 3.
    Whitehead, V. M., Perrault, M. M., and Stelcner, S., Cancer Res., 35, 2985–2900 (1975).PubMedGoogle Scholar
  4. 4.
    Galivan, J., Cancer Res., 39, 735–743 (1979).PubMedGoogle Scholar
  5. 5.
    Whitehead, V. M., Cancer Res., 37, 408–412 (1977).PubMedGoogle Scholar
  6. 6.
    Jacobs, S. A., Adamson, R. H., Chabner, B. A., Derr, C. J., and Johns, D. G., Biochem. Biophys. Res. Commun., 63, 692–698 (1975).PubMedCrossRefGoogle Scholar
  7. 7.
    Sirotnak, F. M., Chello, P. L., Piper, J. R., and Montgomery, J. A., Biochem. Pharm., 27, 1821–1825 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    Werkheiser, W. C, Cancer Res., 23, 1277–1285 (1963).PubMedGoogle Scholar
  9. 9.
    Nair, M. G., and Baugh, C. M., Biochemistry, 12, 3923–3927 (1973).PubMedCrossRefGoogle Scholar
  10. 10.
    Galivan, J., Mol. Pharm., 17, 105–110 (1980).Google Scholar
  11. 11.
    Schilsky, R. L., Barteg, B. D., and Chabner, B. A., Proc. Natl. Acad. Sci., 77, 2919–2922 (1980).PubMedCrossRefGoogle Scholar
  12. 12.
    Sirotnak, F. M., Pharmac. Thera., 8, 71–103 (1980).CrossRefGoogle Scholar
  13. 13.
    Hutchison, D. J., Robinson, D. L., Martin, D., Ittensohn, O. L., and Dillenberg, Cancer Res., 22, 57–72 (1962).PubMedGoogle Scholar
  14. 14.
    Sirotnak, F. M., Donati, G. J., and Hutchison, D. J., J. Bacteriol., 85, 658–665 (1963).PubMedGoogle Scholar
  15. 15.
    Philips, F. S., Sirotnak, F. M., Sodergren, J. E., and Hutchison, D. J., Cancer Res., 33, 153–158 (1973).PubMedGoogle Scholar
  16. 16.
    Hutchison, D. J., Philips, F. S., Schmid, F. A., Sodergren, J. E., and Sternberg, S. S., Proc. Amer. Assoc. Cancer Res., 13, 18 (1972).Google Scholar
  17. 17.
    Sirotnak, F. M., and Donsbach, R. C., Cancer Res., 15, 1737–1744 (1975).Google Scholar
  18. 18.
    Coward, J. K., Chello, P. L., Cashmore, A. R., Parameswaran, K. N., DeAngelis, L. M., and Bertina, J. R., Biochemistry, 14, 1538–1552 (1975).CrossRefGoogle Scholar
  19. 19.
    Sirotnak, F. M., and Hachtel, S. L., Genetics, 61, 293–312 (1969).PubMedGoogle Scholar
  20. 20.
    Rosenblatt, D. S., Whitehead, V. M., Vera, N., Pottier, A., Dupont, M., and Vuchich, M.-J., Mol. Pharm., 14, 1143–1147 (1978).Google Scholar
  21. 21.
    Poser, R. G., Sirotnak, F. M., and Chello, P. L., Biochem. Pharmacol., 29, 2701–2704 (1980).PubMedCrossRefGoogle Scholar
  22. 22.
    Sirotnak, F. M., and Moccio, D. M., Cancer Res., 40, 1230–1234 (1980).PubMedGoogle Scholar
  23. 23.
    Dembo, M., and Sirotnak, F. M., Biochem. Biophys. Acta, 448, 505–516 (1976).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Richard G. Poser
    • 1
  • Francis M. Sirotnak
    • 1
  1. 1.Laboratory for Molecular TherapeuticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations